Drugs / E-Aminocaproic acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02257580 | Apr 2015 → Oct 2020 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E-Aminocaproic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02257580 ↗ |
| Action | Inhibit | “competitively inhibits the activation of plasminogen to plasmin” NCT02257580 ↗ |
| Modality | Small molecule | “E-Aminocaproic acid (EACA) is a synthetic lysine analog” NCT02257580 ↗ |
| Route | Intravenous | “IV EACA reduces intra-operative calculated total blood loss” NCT02257580 ↗ |